The FDA approved ubrogepant (Ubrelvy, Allergan) for the acute treatment of migraine with or without aura in adults.
Ubrogepant is the first drug in the class of oral calcitonin gene–related peptide receptor antagonists approved for the acute treatment of migraine. It is approved in two dose strengths (50 and 100 mg). However, the drug is not indicated for the preventive treatment of migraine.
“Migraine is an often disabling condition that affects an estimated 37 million people in the